Australia's April 12 Deadline for Raising the Bar

26 March 2013 PharmaPatents Blog

Now that we have made it past the March 16, 2013 effective date of the first-inventor-to-file provisions of the America Invents Act, it is time to turn our attention to Australia, and the April 15, 2013 effective date of the Intellectual Property Laws Amendment (Raising the Bar) Act.

Raising the Bar

The Raising the Bar Act will impose stricter substantive requirements, including:

  • Adopting a global view of “common general knowledge” that can be used to support an inventive step (obviousness) rejection.
  • Requiring an application to disclose a “specific, substantial, and credible use” for the invention.
  • Requiring the description to be “clear enough and complete enough” for a skilled person to perform the invention.
  • Replacing the “fair basis” rule for written description with a requirement that the claims be “supported by the matter disclosed” in the application as filed.

Many of the new standards are drawn from U.S. and EPO practice, and are aimed at making the threshold requirements for obtaining a patent comparable to those of the U.S., EPO and JPO.

Getting in Under the Bar

Applications for which a Request for Examination is filed on or after April 15, 2013 will be examined under the new law. Thus, in order to obtain examination under current Australian patent law, both the application and Request for Examination must be filed by Friday, April 12, 2013. Stakeholders who are concerned about these changes might consider filing Requests for Examination in pending applications, and filing new applications (including national stage applications) with a Request for Examination, all within the next few weeks.

New Infringement Exceptions

The Raising the Bar Act included two new infringement exceptions which took effect on April 16, 2012.

  1. Regulatory Use Exemption: Exempts from infringement all activities necessary to obtain regulatory approval for non-pharmaceutical products (e.g., agricultural chemicals, medical devices). (Activities necessary to obtain regulatory approval for pharmaceutical products already were exempted by provisions similar to 35 USC § 271 (e)(1))
  2. Experimental Use Exemption: Exempts from infringement “work done for experimental purposes relating to the subject matter of the invention,” such as “determining the properties of the invention; determining the scope of a patent claim relating to the invention; improving or modifying the invention; determining the validity of the patent or of a patent claim relating to the invention, and determining whether the patent for the invention would be, or has been, infringed by the doing of an act.”

For More Information … 

For more information, please see the IP Reforms page of the IP Australia Web site.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services


Ten Minute Interview: Private Market Investments
07 December 2022
CMS Extends Delayed Enforcement of the Good Faith Estimate
07 December 2022
Health Care Law Today
Tech M&A Outlook: What Types of Deals are Getting Done?
07 December 2022
Foley Ignite
Foley Automotive Report
06 December 2022
Dashboard Insights
What You Should Know About Payor/Provider Convergence
25-26 January 2023
Los Angeles, CA
ATA EDGE2022 Policy Conference | American Telemedicine Association
7-9 December 2022
Washington, D.C.
CLE Weeks
5-16 December 2022
Milwaukee, WI
Foley Sponsors Ernst & Young Entrepreneur of the Year® Program
1 December 2021 - 30 November 2022
Michigan and Northwest Ohio Region